Verseau Therapeutics launches with focus on immunotherapies

Pharmaceutical Technology | October 22, 2019

Verseau Therapeutics has launched to develop immunotherapies that act as checkpoint modulators of macrophages, inducing an immune response against cancer. The company received a $50m investment from 3SBio, 20 / 20 HealthCare Partners, Yonghua Capital, The Mark Foundation for Cancer Research, InHarv Partners, Highlight Capital and Alexandria Venture Investments. Verseau Therapeutics will use the funds to advance macrophage checkpoint modulator (MCM) programmes into the clinic. Macrophages exhibit a variety of functional responses such as pro-inflammatory and anti-inflammatory immune responses. The company has licensed the siRNA delivery technology from the MIT laboratories. It intends to leverage the technology, among similar delivery approaches, with its all human translational system to identify and validate macrophage targets. The company’s pipeline comprises a PSGL-1 candidate, which reprogrammes macrophages to a pro-inflammatory state, stimulates T-cells and attracts other immune cells to produce a coordinated anti-tumour response.

Spotlight

Following on from our review of trends in the current pharmaceutical R&D pipeline, published in March 2019 this supplement takes a look at the industry’s success stories of 2018 – the drugs which were launched on to the market for the first time during the year. Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. This will include vaccines with novel antigenic components. As such, this list represents a subset of all the first launches which Pharmaprojects reported during 2018, excluding the 67 new drug launches with reformulated or non-NAS moieties, or biosimilars. So, to continue our sports theme this year, we’ll be looking at the drugs which successfully crossed the finishing line, hit the bullseye, and lifted the trophy, to become part of pharma’s elite 2018 team. In pharma as in sport, it’s all about winning. Pharma


Other News
PHARMACY MARKET

DrFirst Pharmacy Solution Earns Edison Award for Excellence in Commercial Technology, Consumer Safety

DrFirst | April 26, 2022

DrFirst's SmartSuite for Pharmacy has earned a prestigious Bronze Edison Award in the Commercial Technology, Consumer Safety Category, honoring the solution's innovative use of artificial intelligence to improve safety for patients and efficiency for pharmacies. The Edison Awards is a global leader in recognizing and honoring the best in innovation and excellence in the development of new products and services to create a positive impact on the world. "Being recognized with an Edison Award is one of the highest accolades a company can receive for innovation in product development and business. We deeply appreciate this recognition for SmartSuite for Pharmacy, which also highlights the dangers posed by medication errors and the need to provide more accurate, efficient technology solutions to hard-working pharmacists." G. Cameron Deemer, president at DrFirs SmartSuite for Pharmacy cleans and accurately translates medication data between incompatible systems, which saves time and can help reduce adverse drug events—the cause of more than 100,000 deaths per year. "The Edison Awards is delighted to recognize DrFirst for its innovation and positive impact on patients and health systems throughout the U.S. with SmartSuite for Pharmacy," said Frank Bonafila, executive director of Edison Awards. This year's Edison Awards finalists were chosen by senior business executives and academics from across the globe, whose votes acknowledge excellence in meeting the award criteria. The awards are named for Thomas Alva Edison, whose extraordinary contributions garnered 1,093 U.S. patents, pioneered multiple industries, and made him a household name worldwide. The 2022 Edison Awards were celebrated April 20 to 22, 2022, in Fort Myers, Florida, at an event hosted by award-winning science and technology journalist Miles O'Brien of PBS NewsHour. SmartSuite for Pharmacy is an AI-powered solution that cross-links an electronic prescription from a provider's EHR to an actual product on the shelf at the receiving pharmacy. It also translates abbreviated medication directions from the electronic prescription into the specific "short codes" used by the receiving pharmacy. Finally, SmartSuite for Pharmacy codifies allergy data for safety checks within the pharmacy workflow. About The Edison Awards The Edison Awards is an annual competition designed to honor excellence in new product and service development, marketing, human-centered design and innovation. Winners represent "game changing" products, services and excellence and leadership in innovation around four criteria: Concept, Value, Delivery and Impact. Started in 1987, The Awards are named after inventor Thomas A. Edison and symbolize the persistence and excellence in innovation personified by him. About DrFirst Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including more than 120,000 prescribers, 70,000 pharmacies, 280 HIS/EHRs, and 1,500 hospitals in the U.S. and Canada.

Read More

PHARMACY MARKET

MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

MediPharm Labs Corp. | February 24, 2022

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects will all require pharmaceutical approved API if commercialized. MediPharm has already shipped good manufacturing practice ("GMP") CBD for development purposes to multiple established pharmaceutical companies. "The filing of a US DMF further advances MediPharm toward its ultimate objective of becoming a dominant supplier of API to pharmaceutical companies. This is a high value, high margin opportunity, and with the only purpose-built facility in North America to receive a domestic GMP licence specifically for the extraction of natural cannabinoids, MediPharm is positioned to capture share in this growing market. In the short to medium term, the DMF unlocks new sales channels and will enable us to further leverage the investments made to date on our high-quality pharmaceutical manufacturing platform. Over the longer-term, it ensures the Company is positioned as the go-to cannabinoid partner for pharmaceutical companies around the world." Bryan Howcroft, CEO, MediPharm About MediPharm Labs Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, API and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.

Read More

BUSINESS INSIGHTS

TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED's lead drug platform candidate ILB®

Tikomed | May 09, 2022

Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed's clinical development, regulatory and commercial strategies. IQVIA brings together deep therapeutic expertise, unparalleled data, and technology alongside flexible operating models to enable biopharma organisations such as TikoMed to accelerate the clinical development and commercialisation of innovative products that improve patient lives. "We are thrilled to have IQVIA involved supporting TikoMed with the next steps in our journey to improve human life by enhancing the body's natural ability to self-repair and regenerate. With our highly scalable proprietary drug platform we aim to provide safe, effective and affordable therapies to as many patients as possible across the globe", CEO Anders Kristensson Fiona Stewart, Head of Strategic Alliance Management Europe from IQVIA said "We are delighted TikoMed has selected IQVIA to strategically collaborate in the development of ILB®. We look forward to leveraging our depth of experience to help accelerate the availability of these medicines to the patients who need them the most." TikoMed was advised by The Connecting Architects on this strategic collaboration. TikoMed AB TikoMed is committed to improve human life by exploring and harnessing the medical potential of the body's ability to self-repair and regenerate. With an adaptive, multi modal mechanism of action, TikoMed's drug platform rebalances the body's inflammatory, immune and fibrotic responses to acute and chronic inflammation in order to enhance self-repair and regeneration. Currently applied as a therapy in neurodegeneration and an enabling technology for advanced therapies, the initial development programs include ALS, TBI and islet cell transplantation. Broader use of the drug platform will be considered for a wider range of diseases using a creative business and financing model. TikoMed's highly scalable proprietary technology aims to provide safe, qualitative and affordable medicine to as many patients as possible across the globe. TikoMed is privately-owned and based in Viken, Sweden. IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility - enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 79,000 employees, IQVIA conducts operations in more than 100 countries.

Read More

PHARMACY MARKET

Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Technologies

Orbit Discovery | March 08, 2022

Orbit Discovery a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid timeframe. Orbit will also utilise other capabilities within WuXi AppTec, in particular their expertise in cell line and assay development and biophysical analysis. Incorporating these capabilities into the Orbit platform will enable functional assays to be developed against a wider range of targets, facilitating direct functional screens using novel bead-based technologies and microfluidics. This is the first strategic technology link Orbit has penned since its formation in 2016. The partnership underlines the commitment of the new management team to deliver ground-breaking technology and broader capabilities to the Partners engaged in applying the Company’s technology for the discovery of peptide therapeutic leads. “We aim to move Orbit to the forefront of peptide discovery, and relationships such as this help us leverage expertise that would take far longer to grow organically. We see the partnership with WuXi AppTec as being a key relationship and a great asset to our current Partners, and Partners of the future.” He added: “We see particular value in the development and manufacturing platform of WuXi AppTec, that will enable us to generate peptides at small or large scale that incorporate chemical modifications to facilitate peptide optimisations and the journey towards a therapeutic candidate.” Dr Neil Butt, Chief Executive Officer of Orbit Discovery

Read More

Spotlight

Following on from our review of trends in the current pharmaceutical R&D pipeline, published in March 2019 this supplement takes a look at the industry’s success stories of 2018 – the drugs which were launched on to the market for the first time during the year. Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. This will include vaccines with novel antigenic components. As such, this list represents a subset of all the first launches which Pharmaprojects reported during 2018, excluding the 67 new drug launches with reformulated or non-NAS moieties, or biosimilars. So, to continue our sports theme this year, we’ll be looking at the drugs which successfully crossed the finishing line, hit the bullseye, and lifted the trophy, to become part of pharma’s elite 2018 team. In pharma as in sport, it’s all about winning. Pharma

Resources